B. Metzler seel. Sohn & Co. AG Raises Stock Position in Abbott Laboratories $ABT

B. Metzler seel. Sohn & Co. AG lifted its holdings in Abbott Laboratories (NYSE:ABT) by 1.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,753,889 shares of the healthcare product maker’s stock after buying an additional 26,944 shares during the period. Abbott Laboratories comprises 2.1% of B. Metzler seel. Sohn & Co. AG’s holdings, making the stock its 11th largest holding. B. Metzler seel. Sohn & Co. AG owned approximately 0.10% of Abbott Laboratories worth $234,916,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Charles Schwab Trust Co increased its position in shares of Abbott Laboratories by 109.8% during the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after acquiring an additional 15,394 shares during the period. Asset Management One Co. Ltd. boosted its holdings in shares of Abbott Laboratories by 2.4% in the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after purchasing an additional 19,966 shares during the period. Nordea Investment Management AB grew its stake in Abbott Laboratories by 6.1% in the third quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after purchasing an additional 18,974 shares in the last quarter. AE Wealth Management LLC increased its holdings in Abbott Laboratories by 20.8% during the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after purchasing an additional 11,264 shares during the period. Finally, Mawer Investment Management Ltd. increased its holdings in Abbott Laboratories by 5.9% during the 3rd quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker’s stock worth $168,199,000 after purchasing an additional 70,122 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ABT. Piper Sandler decreased their price objective on Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. Oppenheimer cut their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Royal Bank Of Canada dropped their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Finally, Daiwa Securities Group cut their price objective on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company’s stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Down 1.2%

ABT stock opened at $109.74 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.15. The stock has a market capitalization of $190.69 billion, a PE ratio of 29.50, a price-to-earnings-growth ratio of 1.74 and a beta of 0.74. The firm has a 50 day moving average of $116.09 and a 200 day moving average of $124.63.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s payout ratio is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.